Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 6/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10066924 | 0.82 | LMNA (0.44) | CES2LMNATSHRCCR2TLR4 | |
| SCHEMBL13745963 | 0.82 | CES2 (0.58) | CES2LMNATSHRCCR2GABRR1 | |
| SCHEMBL2874581 | 0.82 | CES2 (0.58) | CES2LMNATSHRCCR2GABRR1 | |
| SCHEMBL1780881 | 0.82 | LMNA (0.44) | CES2LMNATSHRCCR2TLR4 | |
| SCHEMBL18614512 | 0.82 | LMNA (0.44) | CES2LMNATSHRCCR2TLR4 | |
| SCHEMBL13457693 | 0.80 | GABRR1 (0.47) | CES2LMNATSHRCCR2GABRR1 | |
| SCHEMBL14231199 | 0.80 | GABRR1 (0.47) | CES2LMNATSHRCCR2GABRR1 | |
| Hydrochloric Acid SCHEMBL2879189 | 0.80 | CES2 (0.56) | CES2LMNATSHRCCR2GABRR1 | |
| Bromide SCHEMBL9860546 | 0.80 | CES2 (0.56) | CES2LMNATSHRCCR2GABRR1 | |
| SCHEMBL8028496 | 0.80 | LMNA (0.40) | CES2LMNATSHRCCR2GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829030-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2014-09-09 | — | — | US | disclosed |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-04-18 | — | — | US | disclosed |
| US-8357718-B2 | N-heterocyclyl- or cycloalkyl-N-(2-carboxy-5-aryl-3-thiophenyl)cycloalkanecarboxamides, e.g., 5-(3-fluorophenyl)-3-[isopropyl-(4-methylcyclohexanecarbonyl)amino]-thiophene-2-carboxylic acid; especially for prevention and treatment of HVC | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-01-22 | — | — | US | disclosed |
| EP-1569929-B9 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2011-09-14 | — | — | EP | disclosed |
| EP-1569929-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC (CA) | 2010-05-05 | — | — | EP | disclosed |
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
| EP-1569929-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS | Virochem Pharma Inc. (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2005-01-13 | — | — | US | disclosed |
| WO-2004052885-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
| EP-0193280-A2 | Catalyst component for olefin polymerization | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1986-09-03 | — | — | EP | disclosed |
| EP-0173472-A2 | Catalyst component for polymerization of olefins | Tonen Corporation (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0173470-A2 | Catalyst component for polymerization of olefins | Tonen Corporation (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0171155-A1 | Catalyst component for polymerization of olefins | Tonen Corporation (JP) | 1986-02-12 | — | — | EP | disclosed |
| EP-0171200-A2 | Catalyst component for polymerization of olefins | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1986-02-12 | — | — | EP | disclosed |
| US-4565798-A | COORDINATION CATALYSTS, TITANIUM, MAGNESIUM, SILICON COMPOUND | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1986-01-21 | — | — | US | disclosed |
| EP-0157472-A1 | Process for polymerization of olefins | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-10-09 | — | — | EP | disclosed |
| EP-0156512-A1 | Process for preparing catalyst component for polymerization of olefins | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0147053-A1 | A catalyst and a process for polymerization of olefins | Tonen Corporation (JP) | 1985-07-03 | — | — | EP | disclosed |
| EP-0145368-A2 | Process for producing propylene block copolymers | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009804-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | CES2 1250/4885LMNA 1242/4885TSHR 4286/4885 |
| US-20130096106-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, ZYX, ZFX | CES2 1250/4885LMNA 1242/4885TSHR 4286/4885 |
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | CES2 1250/4885LMNA 1242/4885TSHR 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.